Research
Hormonal
In common obesity, endogenous hyperleptinemia fails to inhibit energy intake or increase energy expenditure, a state termed leptin resistance, which is driven by impaired blood-brain barrier transport and intracellular signaling defects (e.g., SOCS-3) in the arcuate nucleus.
Understand that in common obesity, your body's natural 'off switch' for hunger (leptin) is broken or ignored. This is why willpower alone often fails against high-calorie foods. Treatment strategies must bypass this broken signal (e.g., via medications that act downstream or on different pathways) rather than relying on the body's own leptin.
GoodSupportsHIGH confidence
In common obesity, leptin loses the ability to inhibit energy intake and increase energy expenditure; this is termed leptin resistance... Several mechanisms may contribute to leptin resistance. The two hypotheses that have received the most attention are that circulating leptin fails to reach its targets in the brain or that there is a failure of components of the intracellular ObRb signaling cascade.
Why this rating
Strong evidence in animal models (mice); human evidence is debated but acknowledged as existing.
Source
Leptin Resistance and Obesity
Pablo J. Enriori et al. · Obesity · 2006
DOI 10.1038/oby.2006.319
narrative_reviewCited 265×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Leptin regulates energy balance by acting on a dispersed neuronal network in the hypothalamus, specifically activating anorexigenic POMC neurons and inhibiting orexigenic NPY/AgRP neurons in the arcuate nucleus.Strong
- Leptin resistance in humans is debated; some studies suggest low-dose leptin can normalize appetite in weight-reduced obese patients, implying that physiological leptin signaling may still function if the system is resensitized after weight loss.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →